European Translational Oncology Prevention and Screening Institute, Universität Innsbruck, Innsbruck, Austria.
Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nat Aging. 2024 Oct;4(10):1372-1383. doi: 10.1038/s43587-024-00683-3. Epub 2024 Sep 16.
Biomarkers of aging (BOA) are quantitative parameters that predict biological age and ideally its changes in response to interventions. In recent years, many promising molecular and omic BOA have emerged with an enormous potential for translational geroscience and improving healthspan. However, clinical translation remains limited, in part due to the gap between preclinical research and the application of BOA in clinical research and other translational settings. We surveyed experts in these areas to better understand current challenges for the translation of aging biomarkers. We identified six key barriers to clinical translation and developed guidance for the field to overcome them. Core recommendations include linking BOA to clinically actionable insights, improving affordability and availability to broad populations and validation of biomarkers that are robust and responsive at the level of individuals. Our work provides key insights and practical recommendations to overcome barriers impeding clinical translation of BOA.
衰老生物标志物（BOA）是定量参数，可以预测生物年龄，理想情况下还可以预测其对干预措施的变化。近年来，出现了许多有前途的分子和组学 BOA，它们在转化衰老学和延长健康寿命方面具有巨大的潜力。然而，临床转化仍然受到限制，部分原因是临床前研究与 BOA 在临床研究和其他转化环境中的应用之间存在差距。我们调查了这些领域的专家，以更好地了解衰老生物标志物转化的当前挑战。我们确定了临床转化的六个关键障碍，并为该领域制定了克服这些障碍的指导意见。核心建议包括将 BOA 与具有临床可操作性的见解联系起来，提高对广大人群的负担能力和可及性，并验证在个体层面上稳健且有反应的生物标志物。我们的工作为克服阻碍 BOA 临床转化的障碍提供了关键的见解和实用建议。
